Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : A.forall
Deal Size : Inapplicable
Deal Type : Inapplicable
A.forall Launches Fifth ANDA and Second “First Cycle” FDA Approval
Details : A generic version of Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.
Product Name : Precedex-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : A.forall
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sagent Pharmaceuticals Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 Treatment
Details : Enrollment has begun in Sagent"s CAMostat Efficacy vs. pLacebo for Outpatient Treatment of COVID-19, a multicenter, randomized, double-blind, placebo-controlled Phase II trial of the clinical efficacy of Camostat in ambulatory subjects with confirmed COV...
Product Name : Foipan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2020
Lead Product(s) : Camostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Camostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : AdventHealth
Deal Size : Inapplicable
Deal Type : Inapplicable
Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2015
Lead Product(s) : Paracetamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : AdventHealth
Deal Size : Inapplicable
Deal Type : Inapplicable